Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

Haematologica

Volumn 98, Issue 7, 2013, Pages 1098-1106

  Azmi, Asfar S ^a   Al Katib, Ayad ^a   Aboukamee, Amro ^a   Mccauley, Dilara ^b   Kauffman, Michael ^b   Shacham, Sharon ^b   Mohammad, Ramzi M ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Karyopharm Therapeutics   (United States)

^c HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; KPT 127; KPT 185; KPT 205; KPT 227; KPT 251; KPT 276; PROTEIN P53; PROTEIN P73; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR EXPORT SIGNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR VOLUME; WESTERN BLOTTING;

ACRYLATES; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; HUMANS; KARYOPHERINS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME; TRIAZOLES; TUMOR CELLS, CULTURED; WALDENSTROM MACROGLOBULINEMIA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879566083     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.074781     Document Type: Article

References (34)

1. Jemal A. Global burden of cancer: opportunities for prevention. Lancet. 2012;380 (9856):1797-9.
2. Wang X, Zalcenstein A, Oren M. Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. Cell Death Differentiation. 2003;10(4):468-76.
3. Sunters A. Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Can Research. 2006;66(1):212-20.
4. Andre F, Conforti R, Moeder CB, Mauguen A, Arnedos M, Berrada N, et al. Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Ann Oncol. 2012;23(8):2059-64.
5. Turner JG, Sullivan DM.CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chemistry. 2008;15(26):2648-55.
6. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83(8): 1021-32.
7. Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Tren Cell Biol. 2007;17(4):193-01.
8. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucinerich nuclear export signals. Cell. 1997;90(6): 1051-60.
9. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003;4(6): 463-76.
10. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4(2):106-17.
11. Mao L, Yang Y. Targeting the nuclear transport machinery by rational drug design. Curr Pharm Design. 2013;19(12):2318-25.
12. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74(4):648-9.
13. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmernmans PB, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 2009;69(2):510-7.
14. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011;118 (14):3922-31.
15. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2012. pii: S0016-5085(12)01552-1.
16. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, et al. CRM1 blockade by selective inhibitors of nuclear export (SINE) attenuates kidney cancer growth. J Urol. 2013;189(6):2317-26.
17. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621-34.
18. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012;120(9): 1765-73.
19. Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, et al. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. J Hematol Oncol. 2009;2:8.
20. Al-Katib A, Mohammad R, Hamdan M, Mohamed AN, Dan M, Smith MR. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood. 1993;81(11):3034-42.
21. Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, et al. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011;30 (1):117-26.
22. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Can Therapy. 2005; 4(1):13-21.
23. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, et al. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2011;2(5):378-92.
24. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res. 2000;6 (12):4950-6.
25. Cyert MS. Regulation of nuclear localization during signaling. J Biol Chem. 2001;276(24): 20805-8.
26. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer. 2010;46(6):1122-31.
27. Jamali T, Jamali Y, Mehrbod M, Mofrad MR. Nuclear pore complex: biochemistry and biophysics of nucleocytoplasmic transport in health and disease. Int Rev Cell Mol Biol. 2011;287:233-86.
28. Cook A, Bono F, Jinek M, Conti E. Structural biology of nucleocytoplasmic transport. Annu Rev Biochem. 2007;76:647-71.
29. Mosammaparast N, Pemberton LF. Karyopherins: from nuclear-transport mediators to nuclear-function regulators. Trend Cell Biology. 2004;14(10):547-56.
30. Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non- Hodgkin's lymphoma. Clin Cancer Res. 1999;5(5):1085-91.
31. Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell. 1997;90(6):1041-50.
32. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 1999;96(16):9112-7.
33. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23(38):6524-34.
34. Mohammad RM. Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, et al. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2009;8:115.